Table 1.
Baseline characteristics of patients with chronic stable heart failure
| Variable | Value |
|---|---|
|
| |
| Demographics: | |
| Mean Age (years) | 53 ±13 |
| Male gender (%) | 76 |
| African-American (%) | 15 |
|
| |
| Heart failure etiology and functional class: | |
| Non-ischemic cardiomyopathy (%) | 55 |
| Chemotherapy-induced (%) | 10 |
| Valvular disease (%) | 6 |
| Ischemic etiology (%) | 29 |
| NYHA Functional Class (I/II/III, %) | 10/70/20 |
|
| |
| Exhaled Nitric Oxide (ppb): | |
| Resting | 17 (13.5–21.5) |
| Post-exercise | 20 (17–31) |
|
| |
| Echocardiographic Data: | |
| LV ejection fraction (%) | 31 (25–40) |
| LV end-diastolic dimension (cm) | 6.0 ±1.1 |
| LV end-systolic volume index (ml/m2) | 60.6 (38.6–97.5) |
| RV myocardial performance (Tei) index | 0.62 ±0.24 |
| RV systolic pressure (mmHg) | 35 (30–42) |
| LA volume index (ml/m2) | 31.4 (22.7–50.3) |
| Mitral E/Average Ea | 9.8 (6.7–20.4) |
|
| |
| Comorbidities: | |
| Diabetes mellitus (%) | 30 |
| Hypertension (%) | 53 |
| Hyperlipidemia (%) | 70 |
| Prior cigarette smoking (%) | 48 |
|
| |
| Medications: | |
| ACE inhibitor/ARBs (%) | 87 |
| Beta-blockers (%) | 91 |
| Loop diuretics (%) | 73 |
| Aldosterone receptor antagonists (%) | 37 |
| Hydralazine (%) | 17 |
| Isosorbide dinitrate (%) | 33 |